• ImmunityBio's Return on Invested Capital (ROIC) is an impressive 300.81%, far exceeding its Weighted Average Cost of Capital (WACC) of 7.85%.
• The company's ROIC to WACC ratio stands at 38.30, indicating significant value creation and capital efficiency.
• Competitors like BridgeBio Pharma, Inc., and Sana Biotechnology, Inc., show negative ROIC figures, highlighting the challenges in the biotech sector.

ImmunityBio, Inc. (NASDAQ:IBRX) is a biotechnology company focused on developing innovative therapies to treat cancer and infectious diseases. The company aims to harness the power of the immune system to fight these diseases, setting it apart in the competitive biotech industry. Key competitors include BridgeBio Pharma, Inc., Sana Biotechnology, Inc., Nkarta, Inc., Allogene Therapeutics, Inc., and Recursion Pharmaceuticals, Inc.

ImmunityBio's Return on Invested Capital (ROIC) is an impressive 300.81%, far exceeding its Weighted Average Cost of Capital (WACC) of 7.85%. This results in a ROIC to WACC ratio of 38.30, indicating that the company is generating returns significantly above its cost of capital. This high ratio suggests that ImmunityBio is using its capital efficiently to create value.

In contrast, ImmunityBio's peers are struggling with negative ROIC figures. For instance, BridgeBio Pharma has a ROIC of -114.85% against a WACC of 7.84%, resulting in a ROIC to WACC ratio of -14.65. Similarly, Sana Biotechnology's ROIC is -105.16% with a WACC of 9.73%, leading to a ratio of -10.81. These figures highlight the challenges faced by these companies in generating returns above their cost of capital.

Nkarta, Inc. has the least negative ROIC to WACC ratio among the peers at -4.97, with a ROIC of -32.24% and a WACC of 6.49%. While still negative, this suggests Nkarta is closer to achieving positive returns compared to its peers. However, it remains far behind ImmunityBio's strong performance.

Overall, ImmunityBio's ability to generate returns well above its cost of capital makes it a standout in the biotechnology sector. Its high ROIC to WACC ratio indicates strong capital efficiency, which could be attractive to investors seeking value creation in this industry.